CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
April 2015—Dako, an Agilent Technologies company, and Ono Pharmaceutical announced a partnership to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer. This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo. Opdivo is an investigational programmed cell death-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T cells.
Dako , +45 44 85 95 00